Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2147650 | 0.80 | KMT2A (0.65) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL8962380 | 0.79 | LMNA (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8962531 | 0.76 | SMN1; SMN2 (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9843883 | 0.75 | KMT2A (0.50) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9390816 | 0.74 | SMN1; SMN2 (0.50) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8962536 | 0.74 | SOAT1 (0.44) | KMT2ALMNASMN1; SMN2SOAT1 | |
| SCHEMBL7568033 | 0.74 | PTGES (0.47) | — | |
| SCHEMBL8962535 | 0.73 | SMN1; SMN2 (0.60) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL8962550 | 0.73 | NLRP3 (0.58) | — | |
| SCHEMBL8962577 | 0.72 | TSHR (0.46) | KMT2AMEN1LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |